Caruso, I.
Di Gioia, L.
Di Molfetta, S.
Caporusso, M.
Cignarelli, A.
Sorice, G. P.
Laviola, L.
Giorgino, F. http://orcid.org/0000-0001-7372-2678
Funding for this research was provided by:
National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”.
Università degli Studi di Bari Aldo Moro
Article History
Received: 24 May 2024
Accepted: 2 August 2024
First Online: 14 August 2024
Declarations
:
: AC: AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diagnostics, Sanofi Aventis. FG: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Medimmune, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis. GPS: Amgen, Amryt, Eli Lilly, Farmitalia, Novo Nordisk, Sanofi; IC: Eli Lilly, Novo Nordisk; LDG: Eli Lilly, Lusofarmaco, Medtronic, MOVI SpA, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis. LL: Abbott, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Merck Sharp & Dohme, Medtronic, Menarini, MOVI SpA, Mundipharma, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis, Terumo. MC: AstraZeneca, Eli Lilly, Guidotti, Novo Nordisk; SDM: Ascensia Diabetes Care, Eli Lilly, MOVI SpA, Roche Diabetes Care.